Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Delpazolid

Phase 2Small molecule

LLigaChem Biosciences, Inc.

Delpazolid is one of 39 small molecule programs targeting Abscess. It is currently in Phase 2.

2

Indications

5

Total Trials

2

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

Nontuberculous Mycobacterium InfectionCompleted

AbscessPhase 2

Active, not recruiting

Nontuberculous Mycobacterium InfectionPhase 2

Completed

Competition

Competitive Landscape

64 competitors in Abscess

#DrugCompanyPhaseTrials

Valtrex

GGlaxo Dba Glaxosmithkline

Flagyl

DDePuy Orthopaedics

Duragesic

Activase

Mycobutin

Primaxin

Biaxin

Sirturo

MS Contin

HHikma Pharmaceuticals LLC

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

ESS

NCT06114628

Q4 2027

Phase 2Recruiting

NAC

NCT05807399

Clinical

Trials by Indication[1]

NAC2 trials

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

Completed·LLigaChem Biosciences, Inc.·Phase 2·NCT04550832·76 enrolled

ESS1 trial

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting·UUniversity College, London·Phase 2·NCT06114628·2,500 enrolled

Vancomycin1 trial

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

Terminated·LLigaChem Biosciences, Inc.·Phase 2·NCT05225558·40 enrolled

Nontuberculous Mycobacterium Infection1 trial

A Phase 2a, Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of LCB01-0371 (Delpazolid) as Add-on Therapy in Patients With Refractory Mycobacterium Abscessus Complex Pulmonary Disease

Completed·LLigaChem Biosciences, Inc.·Phase 2·NCT06004037·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Delpazolid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Delpazolid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Delpazolid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LigaChem Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLigaChem Biosciences, Inc.

Related News